| Brookside Energy Limited (BRK) ORDINARY FULLY PAID |
Energy |
$37 |
MST & NWR Webinar- Next Generation of ASX Oil & Gas Winners
|
11 Feb 2026 8:17AM |
$0.420 |
$0.385 |
fallen by
8.33%
|
|
| Argenica Therapeutics Limited (AGN) ORDINARY FULLY PAID |
Health Care |
$15 |
Half Yearly Report and Accounts
|
11 Feb 2026 8:17AM |
$0.285 |
$0.120 |
fallen by
57.89%
|
|
AGN - Price-sensitive ASX Announcement
Full Release
Key Points
- Argenica Therapeutics Limited reported a net loss of $3,816,831 for the half-year ended 31 December 2025.
- Total income decreased significantly from $3,107,366 in the previous period to $720,169.
- Research and development expenses were the largest expenditure, amounting to $3,032,222.
- Net assets at 31 December 2025 were $3,443,280, a decrease from $7,237,271 on 30 June 2025.
- The company received government grants totaling $626,739 during the half-year.
- Cash and cash equivalents decreased to $5,037,373 from $10,555,160 at the start of the period.
- The company is involved in the development of a neuroprotective therapeutic drug, specifically in Phase 2 trials for ischemic stroke patients.
- There were no dividends declared for the half-year ended 31 December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Everest Metals Corporation Ltd (EMC) ORDINARY FULLY PAID |
Materials |
$26 |
Corporate Presentation
|
11 Feb 2026 8:17AM |
$0.150 |
$0.098 |
fallen by
34.67%
|
|
EMC - Price-sensitive ASX Announcement
Full Release
Key Points
- Everest Metals Corporation Ltd (EMC) is focused on mineral exploration and development.
- EMC has projects in gold and critical minerals, particularly rubidium and lithium.
- The Revere Gold Project targets prolific gold mineralisation with a maiden JORC resource expected by Q2, 2026.
- The Mt Edon Project is pioneering Australia's rubidium industry, boasting a maiden inferred JORC compliant resource.
- EMC's Mt Dimer Taipan Gold Project has high-grade gold and silver systems with ongoing mining activities.
- The Mt Edon project aims to become a leading producer of rubidium chloride, with a pilot plant expected by late 2026.
- EMC is working towards vertical integration for downstream processing of rubidium and lithium compounds.
- Environmental and heritage surveys have been completed in compliance with local regulations.
- EMC is undertaking various drilling programs to expand resources and define new mineral zones.
- The company is actively engaging in research and development to improve extraction technologies for rubidium.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cosmo Metals Limited (CMO) ORDINARY FULLY PAID |
Materials |
$4 |
Prospectus - Entitlement Offer
|
11 Feb 2026 8:16AM |
$0.013 |
$0.006 |
fallen by
53.85%
|
|
CMO - Price-sensitive ASX Announcement
Full Release
Key Points
- Cosmo Metals Limited is conducting a non-renounceable pro rata entitlement offer.
- The entitlement offer aims to raise approximately $1.55 million before costs.
- Eligible Shareholders can apply for five new shares for every fourteen shares held.
- Each new share is priced at $0.01 with one attaching new option for every four new shares.
- The new options are exercisable at $0.015 and expire on April 3, 2028.
- The funds will be used for drilling activities at various projects, working capital, and corporate overheads.
- The entitlement offer is fully underwritten by Discovery Capital Partners Pty Ltd.
- A shortfall offer will be made for any shares not subscribed for under the entitlement offer.
- The offer is open to shareholders in Australia, New Zealand, and Singapore.
- The offer period is from February 18, 2026, to March 9, 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Spheria Emerging Companies Limited (SEC) ORDINARY FULLY PAID |
Financials |
$140 |
Net Tangible Asset Backing
|
11 Feb 2026 8:16AM |
$2.680 |
$2.340 |
fallen by
12.69%
|
|
| Southern Cross Electrical Engineering Ltd (SXE) ORDINARY FULLY PAID |
Industrials |
$1,336 |
Contract awards totalling $75m
|
11 Feb 2026 8:16AM |
$2.750 |
$4.400 |
risen by
60%
|
|
SXE - Price-sensitive ASX Announcement
Full Release
Key Points
- Contract awards totaling $75 million
- Projects in Western Australia, New South Wales, and the ACT
- Master Services Agreement with CITIC Pacific for Sino Iron Project
- Electrical works for data centre in Sydney with Taylor Construction
- Main electrical package for Canberra Lyric Theatre with Multiplex
- Fire services contract for Sydney distribution centre with Richard Crookes
- Demonstrates geographic and sector diversity
- Repeat works with existing clients and sites
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IGO Limited (IGO) ORDINARY FULLY PAID |
Materials |
$5,687 |
1H26 Half Year Results Webcast
|
11 Feb 2026 8:16AM |
$8.380 |
$7.510 |
fallen by
10.38%
|
|
| Caprice Resources Limited (CRS) ORDINARY FULLY PAID |
Materials |
$73 |
Drilling Confirms Extensions to High-Grade Gold at Vadrians
|
11 Feb 2026 8:16AM |
$0.088 |
$0.084 |
fallen by
4.55%
|
|
CRS - Price-sensitive ASX Announcement
Full Release
Key Points
- Caprice Resources Ltd confirms extensions to high-grade gold at Vadrians.
- Significant drilling results from the Island Gold Project (IGP) show promising extensions to the Vadrians high-grade gold lode.
- RC hole 25IGRC091 intersected 9m at 7.3 g/t gold, extending the Vadrians high-grade lode by over 80m.
- Phase 4 diamond drilling extended gold mineralisation to more than 1,000m of strike and at least 400m depth.
- A new high-grade quartz reef discovery was identified in the Vadrians footwall, presenting a new growth target.
- Pending assay results for five diamond holes and 160 AC holes are expected in February and March 2026.
- Further RC drilling is planned to target northern strike extensions and additional depth extensions at Vadrians.
- Caprice's Managing Director Luke Cox highlighted the sustained period of exploration and assay results expected.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Forrestania Resources Limited (FRS) ORDINARY FULLY PAID |
Materials |
$603 |
Application for quotation of securities - FRS
|
11 Feb 2026 8:16AM |
$0.520 |
$0.450 |
fallen by
13.46%
|
|
| Forrestania Resources Limited (FRS) ORDINARY FULLY PAID |
Materials |
$603 |
Cleansing Statement
|
11 Feb 2026 8:15AM |
$0.520 |
$0.450 |
fallen by
13.46%
|
|
| SPDR S&P/ASX 200 Fund (STW) |
Financials |
$6,540 |
Daily Fund Update
|
11 Feb 2026 8:15AM |
$79.510 |
$78.990 |
fallen by
0.65%
|
|
| SPDR S&P/ASX 200 Listed Property Fund (SLF) |
Financials |
$492 |
Daily Fund Update
|
11 Feb 2026 8:15AM |
$13.360 |
$12.610 |
fallen by
5.61%
|
|
| SPDR S&P/ASX 50 Fund (SFY) |
Financials |
$715 |
Daily Fund Update
|
11 Feb 2026 8:15AM |
$76.500 |
$76.980 |
risen by
0.63%
|
|
| AGL Energy Limited (AGL) ORDINARY FULLY PAID |
Utilities |
$5,597 |
Appendix 4D and FY26 Half-Year Report
|
11 Feb 2026 8:15AM |
$8.850 |
$8.320 |
fallen by
5.99%
|
|
AGL - Price-sensitive ASX Announcement
Full Release
Key Points
- AGL Energy Limited's total revenue for the half-year ended 31 December 2025 was $4,449 million, an increase of 9.1% compared to the prior year.
- Consumer customer revenue increased by 10.6% to $2,877 million due to higher wholesale energy and network costs as well as increased volumes.
- A 5.7% increase in total revenue was recorded, amounting to $1,441 million.
- Operating costs (excluding depreciation and amortisation) decreased by 3.0% to $877 million.
- Customer electricity sales volumes increased by 1.4% to 18,422 GWh.
- AGL recognized $55 million pre-tax for the Retail Transformation Program and $9 million for other transition costs.
- Total capital expenditure amounted to $652 million, with sustaining capital expenditure increasing to $438 million.
- Total network costs rose by 9.5% to $1,414 million due to higher consumer volumes and tariff rates.
- Green compliance costs increased by 23.4% to $411 million.
- AGL's income tax expense for the half-year ended 31 December 2025 was $41 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| James Hardie Industries Plc (JHX) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$12,528 |
Q3 FY26 Results Pack
|
11 Feb 2026 8:05AM |
$33.240 |
$37.010 |
risen by
11.34%
|
|
JHX - Price-sensitive ASX Announcement
Full Release
Key Points
- Net sales increased by 30% to $1,239.8 million.
- Net income decreased by 52% to $68.7 million.
- Operating income decreased by 15%, with a margin drop to 14.2%.
- Adjusted EBITDA increased by 26%.
- Siding & Trim segment sales increased by 10%.
- Deck, Rail & Accessories segment faced an operating loss.
- AZEK integration surpassed cost synergy goals.
- Adjusted net income decreased by 7% to $142.2 million.
- Adjusted diluted earnings per share decreased from $0.36 to $0.24.
- Future revenue synergies expected due to integration success.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Truscreen Group Limited (TRU) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Health Care |
$12 |
TruScreen Validated as Superior Primary Screening Tool
|
11 Feb 2026 8:03AM |
$0.016 |
$0.012 |
fallen by
25%
|
|
TRU - Price-sensitive ASX Announcement
Full Release
Key Points
- TruScreen validated as superior primary cervical cancer screening tool.
- Study conducted in 64 hospitals across 9 provinces in China.
- 14,982 women participated in the study from 2018 to 2021.
- TruScreen compared with LBC and hrHPV testing.
- Results showed superior sensitivity and negative predictive value.
- Study published in BMC Cancer journal.
- Technology suitable for areas with low pathology infrastructure.
- Potential to significantly enhance global cervical cancer screening rates.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SGH Limited (SGH) ORDINARY FULLY PAID |
Industrials |
$18,156 |
Dividend/Distribution - SGH
|
11 Feb 2026 7:46AM |
$49.150 |
$44.610 |
fallen by
9.24%
|
|
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$58,336 |
CSL Half Year Results Investor Presentation
|
11 Feb 2026 7:46AM |
$171.390 |
$121.810 |
fallen by
28.93%
|
|
CSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue for 1H26 was $8.3 billion, a 4% decrease at constant currency.
- NPATA was $1.9 billion, down 7% from the previous period.
- Reported NPAT was $401 million, reflecting an 81% decline.
- Strong cash flow of $1.3 billion and leverage ratio at 2.0x.
- Expanded share buyback from US$500 million to US$750 million.
- Focus on transformation and growth initiatives in US and China.
- Targeted 2-3% revenue growth and 4-7% NPATA growth for 2H26.
- Significant investment in R&D and cost-saving initiatives.
- Restructuring and impairment costs impacted financials.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$58,336 |
Dividend/Distribution - CSL
|
11 Feb 2026 7:43AM |
$171.390 |
$121.810 |
fallen by
28.93%
|
|
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$58,336 |
CSL Half Year Results Announcement
|
11 Feb 2026 7:41AM |
$171.390 |
$121.810 |
fallen by
28.93%
|
|
CSL - Price-sensitive ASX Announcement
Full Release
Key Points
- CSL Limited reported a half-year NPATA of US$1.9 billion for the six months ended 31 December 2025.
- Total revenue for the period was US$8.3 billion, marking a 4% decline.
- Reported net profit after tax was US$401 million, down 81%.
- The company's performance was affected by governmental policy changes, restructuring costs, and impairments.
- CSL expanded its share buy-back program to US$750 million.
- Guidance for FY26 includes expected revenue growth of 2-3% and NPATA growth of 4-7%.
- Transformation initiatives led to achieving 60% of targeted cost savings for FY26.
- CSL Behring revenue dropped 7%, with Ig product sales down 6%.
- CSL Seqirus revenue was down 2%, and CSL Vifor revenue increased by 12%.
- The company is investing in high-priority growth initiatives including a collaboration with VarmX.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$58,336 |
CSL Statutory Accounts for the Half Year Ended 31 December
|
11 Feb 2026 7:41AM |
$171.390 |
$121.810 |
fallen by
28.93%
|
|
CSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue for the half-year ended 31 December 2025 was US$8.3 billion, down 2%.
- Net profit after tax (NPAT) attributable to CSL shareholders fell by 80% to US$0.4 billion.
- Significant impairments and restructuring costs of US$1.4 billion impacted profit.
- Restructuring costs for fiscal year 2026 expected to be US$700-$770 million.
- Investment in U.S. plasma manufacturing expansion and VarmX collaboration.
- Strong balance sheet with net assets of US$20.5 billion.
- Cash flows from operations increased by 3% to US$1.3 billion.
- Unfranked interim dividend of US$1.30 per share announced.
- Company's transformation initiatives aim to simplify operations and enable growth.
- Exchange rate variations and competitive pressures affected financial results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Commonwealth Bank of Australia (CBA) ORDINARY FULLY PAID |
Financials |
$276,155 |
CBA Remedial Action Plan sustainability review
|
11 Feb 2026 7:34AM |
$158.740 |
$165.020 |
risen by
3.96%
|
|
| Fletcher Building Limited (FBU) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Industrials |
$2,969 |
Sale of Felix Street property
|
11 Feb 2026 7:32AM |
$3.150 |
$2.760 |
fallen by
12.38%
|
|
| SGH Limited (SGH) ORDINARY FULLY PAID |
Industrials |
$18,156 |
Presentation of Half Year Results
|
11 Feb 2026 7:32AM |
$49.150 |
$44.610 |
fallen by
9.24%
|
|
SGH - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for HY26 was $5.4 billion, slightly down from HY25.
- EBIT remained stable at $844 million.
- Net profit after tax increased by 2% to $518 million.
- Operating cash flow rose by 32% to $1,084 million.
- Adjusted Net Debt to EBITDA ratio improved by 4%.
- Industrial Services EBIT increased by 1%, led by Boral.
- Safety and sustainability were key focus areas, with improved injury rates.
- SGH remains a market leader in Australian Industrials and Energy.
- The company is focused on strategic growth and operational efficiency.
- SGH is listed on the ASX100 with a $20 billion market capitalisation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Commonwealth Bank of Australia (CBA) ORDINARY FULLY PAID |
Financials |
$276,155 |
Update - Notification of buy-back - CBA
|
11 Feb 2026 7:32AM |
$158.740 |
$165.020 |
risen by
3.96%
|
|
Call 1300 880 160
Start a chat
Schedule a call
